Revenue segments as reported by the company.

Cardiovascular

Medical Surgical

Neuroscience

Diabetes

Other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Selling, general, and administrative

Amortization of intangible assets

Restructuring charges, net

Certain litigation charges, net

Other operating expense, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Medtronic

Medtronic Plc is a medical technology company, which engages in the development, manufacture, distribution, and sale of device-based medical therapies and services. It operates through the following segments: Cardiovascular Porrtfolio, Neuroscience Portfolio, Medical Surgical Portfolio, and Diabetes Operating Unit. The Cardiovascular Portfolio segment includes products for the diagnosis, treatment, and management of cardiac rhythm disorders and cardiovascular disease. The Neuroscience Portfolio is made up of cranial and spinal technologies, specialty therapies, and neuromodulation divisions. The Medical Surgical Portfolio is comprised of surgical innovations and respiratory, gastrointestinal, and renal divisions. The Diabetes Group segment offers insulin pumps, continuous glucose monitoring systems, and insulin pump consumables. The company was founded in 1949 and is headquartered in Dublin, Ireland.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Medtronic reports strong Q4 results, anticipates margin pressures for FY '24

MDT reported strong Q4 results with organic revenue growth, but anticipates margin pressures and EPS decline for FY '24. They highlighted successful FDA approvals and expressed confidence in growth opportunities.

Medtronic reports strong Q2 earnings, highlights growth opportunities

Medtronic's Q2 earnings call showcased strong financial performance, with raised full-year guidance. The company emphasized growth in key business segments and highlighted opportunities in insulin-dependent patient solutions and AI-powered solutions. Challenges include delays in PMRI spend and minimal impact of GLP-1s on the business.

Medtronic exceeds Q3 expectations, focuses on growth and transformation

Medtronic's Q3 earnings call highlighted strong performance, raised outlook, and a focus on transformation for sustainable growth. The company is strategically addressing challenges through cost reduction efforts and seizing opportunities in key markets. Medtronic remains committed to driving innovation and maximizing shareholder value.

Medtronic exceeds Q4 expectations, eyes growth in innovative healthcare

Medtronic's Q4 performance showcased strong growth in key segments, with a focus on innovation and market expansion. Despite challenges from inflation and currency impact, the company remains optimistic about future growth opportunities driven by product advancements and strategic acquisitions.

Medtronic reports robust Q1 results, eyes growth amid challenges

Medtronic's Q1 performance showcased strong revenue growth and emphasized innovation across key business segments.
While facing challenges of growth deceleration and margin expansion, the company remains focused on operational efficiencies and market fundamentals.
Opportunities lie in bariatric space growth, ongoing transformation efforts, and advancements in diabetes programs and surgical systems.
Overall, Medtronic's strategic investments in technology, pricing strategies, and procedural trends position it for continued success and market leadership.

Medtronic surpasses revenue expectations, eyes growth in key markets

Medtronic delivered strong Q2 results with revenue growth ahead of expectations and raised full-year guidance. Despite concerns about GLP-1 drugs and the SELECT trial, the company remains optimistic about growth prospects, focusing on key markets and product innovation.

Medtronic reports solid Q3 growth, focuses on innovation and profitability

Medtronic's Q3 earnings call showcased strong financial performance, international market growth, and strategic decisions to drive innovation and profitability. The company's focus on new technologies, portfolio management, and overcoming challenges highlights a path towards sustained growth and earnings leverage. With positive progress in key business segments and a commitment to future profitability, Medtronic is well-positioned for continued success.

Medtronic reports robust Q4 growth, eyes operational efficiency and China

Medtronic's Q4 2024 earnings call highlighted strong revenue growth, new product launches, and a focus on restoring earnings power. The company provided guidance for fiscal year '25, expecting organic revenue growth, operating margin expansion, and non-GAAP diluted EPS. Analyst questions centered on EPS guidance, revenue growth drivers, and operational efficiencies.

Medtronic reports solid Q1 results, raises guidance for fiscal '25

Medtronic's Q1 2025 performance reflects steady revenue growth and increased EPS, driven by strong performances in key business segments and global markets.
The company's focus on innovation, strategic partnerships, and diversified revenue streams positions it well for future growth and market expansion.
While challenges exist in maintaining growth momentum and navigating market complexities, Medtronic's raised guidance and growth expectations signal confidence in its ability to drive top-line growth and restore earnings power.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

DUBLIN, Feb. 28, 2022 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced it will participate virtually in the 42nd annual Cowen healthcare conference on Monday, March 7, 2022. Karen Parkhill, Medtronic executive vice president and chief financial officer, will answer questions on the company beginning at 1:30 p.m.

Medtronic Executive Vice President and CFO to speak at Cowen healthcare conference

DUBLIN, Feb. 28, 2022 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced the launch of the NuVent™ Eustachian tube dilation balloon, which has been cleared by the U.S. Food and Drug Administration (FDA) for the treatment of chronic, obstructive Eustachian Tube Dysfunction. The NuVent™ balloon enables surgeons to deliver treatment in an outpatient or office setting.

Medtronic announces launch of NuVent™ Eustachian tube dilation balloon

Air Products and Chemicals

Atmos Energy

Franklin Resources

Caterpillar

Chubb

Clorox

Cintas Corp

Ecolab

Nucor

PPG Industries

Stanley Black & Decker

Sysco

T. Rowe Price Group

V.F.

Walgreens

NOBL starts the year on a sour note losing 4.08% in January.

My Best Dividend Aristocrats For March 2022

Moderna

Pfizer

Regeneron Pharmaceuticals

Teladoc

Can these top health care stocks be the way to go amidst all the uncertainty in the stock market now?

Best Stocks To Invest In Right Now? 5 Health Care Stocks In Focus

Healthcare collaboration's first Remote Patient Monitoring deployment with St. Mary's General Hospital for Virtual COPD (Chronic Obstructive Pulmonary Disease) program News in Summary First joint deployment for Cloud DX and Medtronic since their announcement of a strategic collaboration Hospital contract with St. Mary's General hospital in Kitchener, Ontario Initial deployment to support Pulmonary Rehab, with growth into other practices in the hospital KITCHENER, ON / ACCESSWIRE / February 23, 2022 / Cloud DX (TSXV:CDX) (OTC:CDXFF), a leading Virtual Care platform, and its partner Medtronic Canada ULC, a subsidiary of global healthcare leader Medtronic plc (NYSE:MDT), signed their first joint Remote Patient Monitoring contract. The contract will support Virtual Care delivery at St. Mary's General Hospital, in Kitchener, Ontario, and will commence with an initial deployment for the hospital's COPD Activation Program.

Cloud DX and Medtronic Sign First Contract with Ontario Hospital

DUBLIN, Feb. 22, 2022 /PRNewswire/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced it received approval from the U.S. Food and Drug Administration (FDA) for InterStim X™ ― the next generation of the InterStim™ portfolio's recharge-free device – and it is available immediately. InterStim systems are the standard of care in advanced therapy options, and the most personalized system, to deliver sacral neuromodulation (SNM) therapy.

Medtronic receives FDA approval for InterStim X™ system, the next generation of the most personalized sacral nerve stimulation therapy for bladder and bowel control

We believe Medtronic historically lost market share as the company does not operate in the high-growth IVD market.

Medtronic: Market Share To Remain Stable

Medtronic plc (MDT) CEO Geoff Martha on Q3 2022 Results - Earnings Call Transcript

Medtronic (MDT) registers organic growth in the Cardiovascular, Neuroscience and Diabetes segments in Q3.

Medtronic's (MDT) Q3 Earnings Beat, Revenues Lag Estimates

DUBLIN, Feb. 22, 2022 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, and the American Society for Gastrointestinal Endoscopy (ASGE) today announced they are working to provide colorectal cancer screening technologies in low income and underserved communities across the United States through the Medtronic Health Equity Assistance Program for colon cancer screening, with support from Amazon Web Services (AWS). The initiative will include the donation of 50 Medtronic GI Genius™ intelligent endoscopy modules to endoscopy centers across the country that can potentially improve the detection of polyps that can lead to colorectal cancer.

Medtronic to provide underserved communities with artificial intelligence (AI)-assisted colonoscopy technology through Health Equity Assistance Program for colon cancer screening

Medtronic (MDT) delivered earnings and revenue surprises of 0.74% and 1.60%, respectively, for the quarter ended January 2022. Do the numbers hold clues to what lies ahead for the stock?

Medtronic (MDT) Q3 Earnings Top Estimates

Medtronic's (MDT) Cardiac Cryoablation is the only ablation catheter approved to treat pediatric AVNRT.

Medtronic's (MDT) Cryoablation Catheters Get FDA Expanded Nod

The surgical supply store reported third-quarter earnings on Tuesday, saying foreign exchange impacts could take a chunk off of top line earnings.

Medtronic's Earnings Fell Short, but Estimates Held Steady

Medtronic MDT, -1.10% said Tuesday it expects procedure volumes in most of its markets to be back to pre-COVID level by the end of the fourth quarter. The medical device maker said its third-quarter net income rose 17% to $1.48 billion, or $1.10 a share, from $1.27 billion, or 94 cents a share, in the year-ago quarter.

Medtronic outlook matches estimates, but Q3 results fall short

Medtronic Plc reported a 16.5% rise in quarterly profit on Tuesday, helped by a strong demand for its pacemakers and other heart devices.

Medtronic quarterly profit jumps 16.5% on strong demand for heart devices

Company advanced its pipeline, launched new products, won share, and delivered earnings growth despite COVID-19 impact on healthcare procedure volumes DUBLIN, Feb. 22, 2022 /PRNewswire/ -- Medtronic plc (NYSE: MDT) today announced financial results for its third quarter of fiscal year 2022, which ended January 28, 2022. "We're transforming Medtronic and committed to durable, higher growth.

Medtronic reports third quarter fiscal 2022 financial results

Butterfly Network

Three digital health stocks are moving the needle for the fast-growing telehealth business. Let's have a look at TDOC, MDT and BFLY.

3 Stocks to Buy as Investors Double Down on Digital Health

Medtronic (MDT) might report low procedure volumes in the fiscal third quarter in markets where its technologies are used in more deferrable procedures.

Medtronic (MDT) to Report Q3 Earnings: What's in Store?

The FDA has approved Medtronic plc's (NYSE: MDT) Freezor and Freezor Xtra Cardiac Cryoablation Catheters to treat pediatric Atrioventricular Nodal Reentrant Tachycardia (AVNRT). The Freezor and Freezor Xtra Catheters are flexible, single-use devices to freeze cardiac tissue and block unnecessary electrical signals within the heart.

Medtronic Scores Expanded FDA Nod For Cardiac Cryoablation Catheters In Pediatric Patients With Heart Rhythm Condition

DUBLIN, Feb. 18, 2022 /PRNewswire/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced that the Freezor™ and Freezor™ Xtra Cardiac Cryoablation Catheters are approved by the U.S. Food and Drug Administration (FDA) and are the only ablation catheters approved to treat the growing prevalence of pediatric Atrioventricular Nodal Reentrant Tachycardia (AVNRT). AVNRT is the most common form of supraventricular tachycardia (SVT), and is a life-threatening abnormal heart rhythm, with 89,000 cases each year and growing.

Medtronic receives FDA expanded approval for cardiac cryoablation catheters for pediatric treatment of a common heart rhythm condition

Steady sales of pacemakers and heart stents may have likely helped Medtronic Plc offset weak demand for its other medical devices, in a quarter that saw an Omicron-led surge in COVID-19 cases and staffing crisis at most U.S. hospitals.

Medtronic's heart device unit may ease earnings pressure from Omicron

Home Depot

Macy's

After markets closed on Thursday, lithium producer Livent reported results that beat on both the top and bottom lines and issued upside revenue guidance for 2022.

Earnings Previews: APA, Home Depot, Macy's, Medtronic, Williams

Dividend champions have raised the dividend for over 25 years and are some of the favorites of dividend growth investors. Using historical PE ratios and historical dividend yields is a simple method for screening for bargains.

2 Crushed Dividend Champions Worth Saving

Medtronic stock is scheduled to report its fiscal third-quarter results on Tuesday, Feb 22. We expect Medtronic to post revenues and earnings above the consensus estimates.

What To Expect From Medtronic's Q3?

In the latest trading session, Medtronic (MDT) closed at $103.91, marking a +1.56% move from the previous day.

News for Medtronic Stock (MDT)